AbbVie (ABBV) Income Statement Flow — TTM through Q2 2026
Calculated from the four most recent reported quarters, ending (reported ).
AbbVie (ABBV) Revenue by Product Segment — TTM through Q2 2026
Aggregated from the four quarterly disclosures behind this TTM. Minor differences vs the company's annual filing can occur if reported segments changed mid-year.
| Segment | Revenue (USD) | % of total |
|---|---|---|
| SKYRIZI | $20.8B | 32.3% |
| RINVOQ | $9.72B | 15.1% |
| Botox Therapeutic | $4.25B | 6.6% |
| Vraylar | $4.15B | 6.4% |
| HUMIRA | $3.89B | 6% |
| Other Products | $3.6B | 5.6% |
| VENCLEXTA | $3.14B | 4.9% |
| Botox Cosmetic | $2.9B | 4.5% |
| Other segments | $11.9B | 18.5% |
| Total | $64.4B | 100% |
- SKYRIZI$20.8B
- RINVOQ$9.72B
- Botox Therapeutic$4.25B
- Vraylar$4.15B
- HUMIRA$3.89B
- Other Products$3.6B
- VENCLEXTA$3.14B
- Botox Cosmetic$2.9B
- Other segments$11.9B
- Total$64.4B
AbbVie (ABBV) Revenue by Geography — TTM through Q2 2026
Aggregated from the four quarterly disclosures behind this TTM. Minor differences vs the company's annual filing can occur if reported regions changed mid-year.
| Region | Revenue (USD) | % of total |
|---|---|---|
| UNITED STATES | $47.9B | 95.8% |
| Non-US | $2.1B | 4.2% |
| Total | $50B | 100% |
- UNITED STATES
- Non-US
- Total
Revenue Breakdown — TTM through Q2 2026
In TTM through Q2 2026, AbbVie (ABBV) reports revenue across 21 reportable product segments; the largest segment was SKYRIZI at 32.3%, followed by RINVOQ (15.1%) and Botox Therapeutic (6.6%). Geographically, UNITED STATES accounted for 95.8% of revenue, followed by Non-US (4.2%).
Frequently asked questions
Data & methodology
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
How this company returns cash to shareholders — buybacks, dividends, and stock splits.